Abstract: The present application discloses a method of forming a hydrogel-coated substrate, wherein the hydrogel has antifouling and antimicrobial properties. The method comprises applying an aqueous pre-hydrogel solution to a substrate, polymerizing the aqueous pre-hydrogel solution, thereby forming a coated substrate having a conformal hydrogel coating and a non-conformal hydrogel coating, contacting the coated substrate with a swelling agent, and removing the non-conformal hydrogel coating from the coated substrate, thereby leaving the conformal hydrogel coating on the substrate to form the hydrogel-coated substrate. The aqueous pre-hydrogel solution comprises a monomer with antimicrobial activity, a monomer with antifouling activity, and either a polymer, oligomer, or macromer which, when polymerized together, form a hydrogel. Also disclosed is a coated substrate and a hydrogel coating.

Abstract: Disclosed are an implantable therapeutic delivery system and methods of treatment utilizing the implantable therapeutic delivery system. The implantable therapeutic delivery system includes a nanofibrous core substrate including one or more internal spaces wherein one or more therapeutic agents is positioned in the one or more internal spaces; and an outer biocompatible polymeric coating surrounding said nanofibrous core substrate.

Abstract: The present disclosure is directed to devices and systems for oxygenating encapsulated cells. The disclosure further relates to individual components of these devices and systems and methods of using the devices and systems to deliver a therapeutic agent to a subject in need thereof.

Abstract: The present invention is directed to a polymer of Formula (IV): wherein A, X, Q, Y, Z, m1, m2, m3, k1, and k2 are as described herein and wherein the monomer units of the polymer are the same or different. The present invention also relates to a monomer of Formula (III): wherein R?, X1, Y1, Z1, m4, m5, and m6 are as described herein, and a polymeric network comprising two or more monomers of Formula (III). The present invention also relates to a hydrogel comprising any of the polymers and monomers described herein, a capsule comprising the hydrogel, and a method of delivering a therapeutic agent to a subject using the capsule.

Abstract: The present application relates to implantable therapeutic delivery system, its method of making and use. The therapeutic delivery system includes a nanofiber core substrate having proximal and distal ends, and an interior nanofiber wall defining an internal space extending longitudinally along the core substrate, with one or more therapeutic agents positioned within the internal space. A hydrogel surrounds the nanofiber core substrate, where the hydrogel includes 0.1% to 20% of an alginate mixture. The alginate mixture includes zwitterionically modified alginate and pure alginate in a ratio of 1:1000 to 1000:1 (v/v). Also disclosed is a thermo sealing device useful for the formation of the implantable therapeutic delivery system.

Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for the encapsulation and transplantation of cells. Also disclosed are high throughput methods for the characterizing the biocompatibility and physiochemical properties of modified alginate polymers.

Abstract: The present invention is directed to a polymer of Formula (IV): wherein A, X, Q, Y, Z, m1; m2, m3, k1; and k2 are as described herein and wherein the monomer units of the polymer are the same or different. The present invention also relates to a monomer of Formula (III), wherein R?, X1, Y1, Z1, m4, m5, and m6 are as described herein, and a polymeric network comprising two or more monomers of Formula (III). The present invention also relates to a hydrogel comprising any of the polymers and monomers described herein, a capsule comprising the hydrogel, and a method of delivering a therapeutic agent to a subject using the capsule.

Abstract: The present application relates to fibers having a diameter of 1 nm to 10,000 nm, of one or more biocompatible polymers, wherein the polymers have a backbone which includes a positively charged component from a zwitterionic moiety. Additionally, this application discloses an implantable therapeutic delivery system and its method of formation, comprising a housing defining a chamber, wherein said housing is porous and formed from the fibers. Inside of the housing includes a preparation of cells which release a therapeutic agent from the chamber. The implantable therapeutic delivery system can be used in the treatment of diabetes.

Abstract: Biomedical devices for implantation with decreased pericapsular fibrotic overgrowth are disclosed. The device includes biocompatible materials and has specific characteristics that allow the device to elicit less of a fibrotic reaction after implantation than the same device lacking one or more of these characteristic that are present on the device. Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.

Abstract: A composition for detoxifying insect pollinators from one or more organophosphate pesticides, the composition containing microparticles comprising: (i) a phosphotriesterase; (ii) nanoparticles; and (iii) a surface active agent. Also disclosed herein is an aqueous suspension comprising the above-described detoxifying microparticles in an external aqueous medium, which may also contain an insect pollinator attractant. Also described herein is a method for detoxifying insect pollinators of one or more organophosphate pesticides, the method comprising placing the detoxifying aqueous suspension in a location accessible to the insect pollinators to permit the insect pollinators to ingest the detoxifying aqueous suspension, wherein the detoxifying aqueous suspension comprises microparticles, as described above, suspended in an external aqueous medium, typically also including an insect pollinator attractant in the external aqueous medium.

Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for the encapsulation and transplantation of cells. Also disclosed are high throughput methods for the characterizing the biocompatibility and physiochemical properties of modified alginate polymers.

Abstract: The present disclosure is directed to an implantable therapeutic delivery device. This device comprises a hydrogel core; one or more therapeutic agents suspended within the hydrogel core; and an elongated nanofibrous substrate having proximal and distal ends, said nanofiber substrate having an interior nanofiber wall defining an internal space that extends longitudinally between the proximal and distal ends of the substrate, wherein the hydrogel core comprising the one or more therapeutic agents is positioned within the internal space. The disclosure is also directed to methods of delivering a therapeutic agent to a subject in need thereof that involves implanting the device described herein.

Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.

Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.

Abstract: The present application relates to copolymers of N-halamine (HA) and dopamine (DMA) and their method of formation. The HA and DMA are present in the copolymer in a ratio of 0.4:9.6 to 9.6:0.4 (HA: DMA). The copolymers can be used in novel antimicrobial compositions that can be coated, and covalently bonded to surfaces such as metal, plastic, glass, or paint surfaces. The coating provides a rechargeable antimicrobial surface with the treatment of a halogen. The coating thickness and halogen content can be tuned by adjusting the formulation and crosslinking the coating.

Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.

Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for the encapsulation and transplantation of cells. Also disclosed are high throughput methods for the characterizing the biocompatibility and physiochemical properties of modified alginate polymers.

Abstract: The present application relates cell replacement devices, comprising a frame cap and a frame base, where the frame cap includes a first connecting member and one or more ports that traverse a thickness of the frame cap. The frame base of the cell replacement device includes one or more walls defining an interior chamber, defining a first opening to the interior chamber on one side of the frame base, and defining a second opening to the interior chamber on another side of the frame base. The first opening of the frame base is configured to receive the frame cap, and the frame base further includes a second connecting member constructed to connect with the first connecting member. The frame base further comprises a mesh disposed adjacent the second opening.

Abstract: Biomedical devices for implantation with decreased pericapsular fibrotic overgrowth are disclosed. The device includes biocompatible materials and has specific characteristics that allow the device to elicit less of a fibrotic reaction after implantation than the same device lacking one or more of these characteristic that are present on the device. Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.

Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.